Dr. Habil Khorakiwala, the founder and chairman of Wockhardt, has been awarded the Lifetime Achievement Award at the 10th Integrated Health & Wellbeing (IHW) Summit held in Dubai. This prestigious award recognizes his significant contributions to the healthcare industry both in India and globally.
Under Dr. Khorakiwala’s leadership, Wockhardt has emerged as a global pharmaceutical company with a strong focus on developing novel antibiotics to combat multi-drug resistant infections. The company’s flagship antibiotic, Zaynich™ (Zidebactam/Cefepime), is currently in a global Phase 3 study, aimed at treating extreme drug-resistant Gram-negative infections. Over the past year, Zaynich™ has already saved the lives of critically ill patients through compassionate use.
Wockhardt’s ongoing commitment to innovation has been highlighted by its development of six novel antibiotics, all of which have received the prestigious Qualified Infectious Disease Product (QIDP) status from the US FDA.
Dr. Khorakiwala’s dedication to healthcare over the past 25 years has not only revolutionized the field of antibiotics but also set a new standard for balancing affordability with excellence in patient care. Wockhardt generates 78% of its revenue from international markets, with a presence in countries such as the USA, UK, Switzerland, and Russia.
The award was accepted on his behalf by Dr. Huzaifa Khorakiwala, Executive Director of Wockhardt, at the event held on September 21, 2024, in Dubai.
